Naslov
Alemtuzumab (Campath) in early MS

Autori
Brinar, Vesna ; Petelin, Željka

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of the 1st World Congress on Controversies in Neurology / - Berlin, 2007, A-2

Skup
1st World Congress on Controversies in Neurology

Mjesto i datum
Berlin, Njemačka, 06.09.2007. - 09.09.2007

Vrsta sudjelovanja
Pozvano predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
relaps-remitirajuća multipla skleroza; alemtuzumab; limfociti; deplecija; betainterferon-1a
(relapsing-remitting multiple sclerosis; alemtuzumab; lymphocytes; depletion; interferon beta-1a)

Sažetak
Alemtuzumab is a humanized monoclonal antibody targeting the CD52 antigen on lymphocytes and monocytes. CAMMS223 Study is a Phase 2, open-label, rater-blinded randomised multicentric study in which treatment-naive patients with early, active relapsing-remitting multiple sclerosis (RRMS) were included. The trial compared safety and efficacy of alemtuzumab to interferon beta-1a (IFNβ -1a ; Rebif). The Referral Center for Demyelinating Diseases of the Central Nervous System at the University Hospital Zagreb included 17 patients with early active RRMS who strictly met all inclusion criteria. The inclusion of patients started in 2003. 11 patients (7F, 4M) were randomised to alemtuzumab, among them 6 to high dose and 5 to low dose alemtuzumab, and 6 (4F, 2M) to interferon beta-1a. Comparing average EDSS at the pre-treatment baseline and after 3 years we found that patients taking high dose alemtuzumab achieved reduction in disability, which was statistically significant in the group taking high dose. IFNβ -1a - treated patients showed slight increase in disability, but the difference was not statistically significant. In the 3-year period patients treated with IFNβ -1a experienced 11 relapses, compared to relapse-free subjects in the alemtuzumab group. Treatment with alemtuzumab was well tolerated. Except two cases of hyperthyroidism, adverse events were generally limited to infusion reactions thet were readily manageable.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA